Clinical trials: 5-FU, completed
Patients With Head and Neck Cancer (ORL)
Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy
Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) is a mainstay for treating head and neck cancers, but elderly or fragile patients are often precluded because of the risk of severe toxicities associated with this protocol.
- Trial name
- 5-FU (NCT02484677)
- Testing
- Cisplatin, Docetaxel, 5-Fluorouracile
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Primary Breast Cancer
Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)
We aimed to evaluate the noninferiority of a short-term anthracycline-free chemotherapy (TC, six cycles of docetaxel and cyclophosphamide) or a short-term anthracycline-based chemotherapy (CEF-T, three cycles of…
- Trial name
- NCT04127019
- Testing
- Paclitaxel, Docetaxel, Cyclophosphamide
- Volunteers
- 2,079 people
- Sponsor
- Fudan University
Metastatic Colorectal Cancer
Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer
The primary objective of this study is to evaluate the efficacy of Irinotecan in combination with FOLFOX+Bevacizumab versus FOLFOX+Bevacizumab alone in the first-line treatment of patients with metastatic colorectal cancer.
- Trial name
- CHARTA (NCT01321957)
- Testing
- Oxaliplatin, 5FU/LV, Bevacizumab, 5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan
- Where
- 51 sites in Germany
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg
Duct Cell Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer
Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer
This phase I trial studies the side effects and best dose of gemcitabine hydrochloride in treating patients with locally advanced pancreatic cancer.
- Conditions
- Duct Cell Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01893294
- Testing
- gemcitabine hydrochloride, fluorouracil, radiation therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
Head and Neck Cancer
Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Trial name
- NCT00608205
- Testing
- cisplatin, fluorouracil, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 69 people
- Sponsor
- Case Comprehensive Cancer Center
Colorectal Cancer
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
PURPOSE: This randomized phase III trial is studying giving oxaliplatin, leucovorin calcium, and fluorouracil together to compare how well they work when given together with or without celecoxib in treating patients with stage…
- Trial name
- NCT01150045
- Testing
- celecoxib, 5-fluorouracil, oxaliplatin
- Where
- 842 sites in United States, Canada and 1 more
- Volunteers
- 2,527 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Locally Advanced and Recurrent/Metastatic Gastric Cancer
Paclitaxel-HDFL for Locally Advanced and Recurrent/Metastatic Gastric Cancers
The purpose of this study is to evaluate the efficacy,response rate,time to treatment failure,overall survival,toxicities of Paclitaxel-HDFL regimen in locally advanced/inoperable and recurrent/metastatic gastric cancers.
- Trial name
- NCT00154726
- Testing
- Paclitaxel-HDFL
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Melanoma, Prostate Cancer
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with…
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma
- Trial name
- IVY (NCT02009449)
- Testing
- Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)
- Where
- 10 sites in United States
- Volunteers
- 353 people
- Sponsor
- Eli Lilly and Company
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer
RATIONALE: Everolimus may stop the growth of stomach or esophageal cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, and oxaliplatin, work in different ways to stop…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT01231399
- Testing
- fluorouracil, leucovorin calcium, oxaliplatin
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- City of Hope Medical Center
Colorectal Cancer
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, irinotecan, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00098787
- Testing
- bevacizumab, fluorouracil, irinotecan hydrochloride
- Where
- 110 sites in United States
- Volunteers
- 247 people
- Sponsor
- Eastern Cooperative Oncology Group
Gastric Cancer, Esophageal Cancer
Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma
The INTEGA study assesses therapy Options for advanced or metastatic esophagogastric Adenocarcinoma in patients overexpressing human epidermal receptor type 2 (HER2 positive patients).
- Conditions
- Gastric Cancer, Esophageal Cancer, Adenocarcinoma Gastric, HER2 Positive Gastric Cancer
- Trial name
- INTEGA (NCT03409848)
- Testing
- Nivolumab, Ipilimumab
- Where
- 35 sites in Germany
- Volunteers
- 97 people
- Sponsor
- AIO-Studien-gGmbH
Squamous Cell Carcinoma
Trial Comparing Two Protocols of re Irradiation in an Irradiated Area for Carcinoma of the Upper Aerodigestive Tract
Patients will be randomised after surgery, provided surgery is macroscopically adequate, that there is a flap of tissue protecting the vascular axis and that wound healing allows reirradiation to begin less than 8 weeks after…
- Trial name
- JANORL2 (NCT01211938)
- Testing
- single-fraction radiotherapy with concomitant 5FU and Hydrea, hyperfractionated radiotherapy with concomitant Cetuximab
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Metastatic Pancreatic Cancer
Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer
Study Part 1: To assess the safety and tolerability, and to characterize the pharmacokinetics (PK) of BAX2398 in combination with 5-FU/calcium levofolinate in Japanese patients.
- Trial name
- NCT02697058
- Testing
- BAX2398 + 5-FU/calcium levofolinate, 5-FU/calcium levofolinate
- Where
- 16 sites in Japan
- Volunteers
- 84 people
- Sponsor
- Institut de Recherches Internationales Servier
Metastatic Colorectal Cancer
QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
This is a phase 2, multicenter, randomized, double-blind, double-dummy, placebo-controlled, three-arm trial to be conducted in the United States, Europe, and Asia.
- Trial name
- NCT00813605
- Testing
- FOLFIRI, AMG 655, AMG 479
- Where
- 67 sites in United States, France and 8 more
- Volunteers
- 155 people
- Sponsor
- NantCell, Inc.
Pancreatic Cancer
Radiation w/FOLFIRINOX-Losartan for Pancreatic Cancer
This is a Phase II clinical trial, which tests the safety and effectiveness of an investigational combination of drugs to learn whether the combination of drugs works in treating a specific cancer.
- Trial name
- NCT01821729
- Testing
- FOLFIRINOX, Losartan, Proton Beam Radiation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Metastatic Biliary Tract Cancer
Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer
The purpose of this study is to evaluate the efficacy and safety of combination of fluorouracil/folinic acid and liposomal irinotecan(Onivyde) compared with fluoruracil/folinic acid in patients with metastatic biliary tract…
- Trial name
- NCT03524508
- Testing
- Onivyde, 5-FU/LV
- Where
- South Korea
- Volunteers
- 178 people
- Sponsor
- Changhoon Yoo
Advanced Well-differentiated Pancreatic Neuroendocrine Tumor
Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor
Temozolomide or dacarbazine-based chemotherapy combined with endostatin have efficacy in well-differentiated pancreatic neuroendocrine tumor
- Trial name
- NCT01845675
- Testing
- temozolomide or dacarbazine-based chemotherapy, endostatin
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Peking Union Medical College Hospital
Colorectal Neoplasms
Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC)
Investigating the efficacy of maintenance and reinduction treatment or no treatment and watchful waiting in subjects with inoperable or irresectable and non-progressive metastatic colorectal cancer after first line induction…
- Trial name
- NCT00973609
- Testing
- 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab
- Where
- Germany
- Volunteers
- 853 people
- Sponsor
- AIO-Studien-gGmbH
Neuroendocrine Tumors
MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents
Neuroendocrine tumors (NET) are rare but their incidence is growing. Alkylating agents (ALKY) are one of the main systemic treatments used, at least for advanced duodeno-pancreatic NETs, with a response rate of 30 to 40% and a…
- Trial name
- MGMT-NET (NCT03217097)
- Testing
- Oxaliplatin-based chemotherapy, Alkylating-based chemotherapy
- Where
- 19 sites in France
- Volunteers
- 116 people
- Sponsor
- Hospices Civils de Lyon
Colorectal Neoplasms
Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer
To assess the safety and tolerability of sunitinib when administered in combination with modified FOLFOX6 in Japanese patients with metastatic colorectal cancer in the first-line treatment setting.
- Trial name
- NCT00631410
- Testing
- sunitinib + mFOLFOX6
- Where
- 3 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.